Results for "CVRx"

Medical device company CVRx has issued a formal response addressing recent correspondence from the Pointillist family office regarding corporate governance and strategic direction.

CVRx forecasts 2026 revenue of $58M-$60M, while AMN projects Q3 revenue of $640M-$655M, with both companies navigating sales productivity and Medicare Advantage headwinds.

CVRx has provided a revenue outlook of $63 million to $67 million for 2026, attributing the projection to changes in prior authorization dynamics following a Category I CPT transition.

CVRx has projected its first-quarter revenue to be in the range of $14.7 million to $14.8 million.

Jorey Chernett, a significant shareholder of CVRx, has publicly called on the company's board to initiate an immediate process to pursue a sale of the company to a strategic acquirer.

CVRx, Lyft, and MARA Holdings have reported mixed second-quarter earnings, with some companies missing EPS estimates while others beat revenue expectations. Lyft, for instance, reported a miss on earnings but a beat on revenue and record active riders.

This article summarizes the key points from CVRx's first-quarter earnings call, covering their financial performance and business developments.

CVRx has revealed that Devoted Health Medicare Advantage will now cover its Barostim Therapy, expanding access for patients.

CVRx shares have seen a rebound after Humana issued a new Medicare policy covering the company's Barostim device.

Several companies, including Parks! America, NET Power, Vodacom, Hypoport AG, and Multi Ways Holdings, have released their latest quarterly or fiscal year financial results. These reports detail their performance over the recent periods.